Journal
TRANSLATIONAL LUNG CANCER RESEARCH
Volume 4, Issue 1, Pages 67-81Publisher
AME PUBLISHING COMPANY
DOI: 10.3978/j.issn.2218-6751.2014.11.06
Keywords
Epidermal growth factor receptor (EGFR); molecular targeted therapy; drug resistance; antineoplastic
Categories
Funding
- Rachelle Archambault Innovation Grant of the Canadian Cancer Society [701637]
- Ontario Ministry of Long Term Health
- Terry Fox Foundation Strategic Initiative for Excellence in Radiation Research for the 21st Century at CIHR and the Ontario Graduate Scholarship fund [EIRR21]
- Poslun family foundation
Ask authors/readers for more resources
Lung cancer is the leading cause of cancer related deaths in Canada with non-small cell lung cancer (NSCLC) being the predominant form of the disease. Tumor characterization can identify cancerdriving mutations as treatment targets. One of the most successful examples of cancer targeted therapy is inhibition of mutated epidermal growth factor receptor (EGFR), which occurs in similar to 10-30% of NSCLC patients. While this treatment has benefited many patients with activating EGFR mutations, almost all who initially benefited will eventually acquire resistance. Approximately 50% of cases of acquired resistance (AR) are due to a secondary T790M mutation in exon 20 of the EGFR gene; however, many of the remaining mechanisms of resistance are still unknown. Much work has been done to elucidate the remaining mechanisms of resistance. This review aims to highlight both the mechanisms of resistance that have already been identified in patients and potential novel mechanisms identified in preclinical models which have yet to be validated in the patient settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available